Cases & Deals

  • Home
  • Practices
  • Innate Pharma S.A. establishes at-the-market program for up to US$75 million in United States

Share

Innate Pharma S.A. establishes at-the-market program for up to US$75 million in United States

April 2023

Client(s) Innate Pharma S.A.

Jones Day represented Innate Pharma S.A., as U.S. counsel, in connection with the establishment of a new at-the-market (ATM) program for up to US$75 million in the United States, including filing a prospectus with the U.S. Securities & Exchange Commission for registered shares on a Form F-3 shelf registration statement. Jefferies LLC acted as sales agent.

Contacts

Before sending, please note:

Information on www.jonesday.com is for general use and is not legal advice. The mailing of this email is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Anything that you send to anyone at our Firm will not be confidential or privileged unless we have agreed to represent you. If you send this email, you confirm that you have read and understand this notice.